DKSH has signed an agreement to acquire all of Dubai-based NewBridge Pharmaceuticals, with an enterprise value of 390 million dollars. NewBridge commercialises specialty and rare-disease medicines across 14 Middle Eastern and North African markets. The debt-financed transaction would extend DKSH Healthcare beyond Asia Pacific. Regulatory approvals remain necessary, with completion expected by the end of the first quarter of 2027.
DKSH, the market expansion services group, signed an agreement to acquire all of NewBridge Pharmaceuticals on October 19. The Dubai-based business commercialises specialty and rare-disease medicines across the Middle East and North Africa. The transaction would take DKSH Healthcare beyond its Asia Pacific base into a new region.[1], [2]
DKSH’s announcement puts the enterprise value at 390 million dollars.[1]
Founded in Dubai in 2010, NewBridge operates in 14 markets, including Saudi Arabia and the United Arab Emirates. Its services include market access, medical affairs and sales-force support for pharmaceutical companies. The portfolio spans oncology, neurology, immunology, gastroenterology and rare diseases. The current multinational management team is expected to join DKSH as part of the acquisition.[1]
DKSH plans to finance the transaction with debt and expects completion by the end of the first quarter of 2027, subject to customary conditions including regulatory approvals. It forecasts around 385 million dollars in NewBridge net sales for 2027 and a high single-digit margin before interest, tax, depreciation and amortisation. Those projections concern future operations; ownership has not yet transferred under the signed agreement.[1]
